Product News
Filter News
Found 270,652 articles
-
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
1/4/2024
Laekna announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah.
-
Angle PLC Announces Breakthrough Clinical Results
1/4/2024
ANGLE plc is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient's cancer and how this may be treated.
-
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
1/3/2024
SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.
-
Entrada Therapeutics Promotes Nathan J. Dowden to President
1/3/2024
Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
-
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
1/3/2024
Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.
-
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
1/3/2024
Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.
-
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
1/3/2024
ABVC BioPharma, Inc. and its subsidiary BioLite, Inc. announced that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc., as its first milestone payment under a global licensing agreement.
-
BioCentriq® Announces the Successful Completion of $29.2M Series A Further Strengthening Cell Therapy Contract Development and Manufacturing Services
1/3/2024
BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization, proudly announces the successful completion of its latest round of fundraising, securing $29.2M in capital investment.
-
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
1/3/2024
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease.
-
Melt Pharmaceuticals Provides Corporate Update - Jan 03, 2024
1/3/2024
Melt Pharmaceuticals, Inc., a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, provided a corporate update.
-
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
1/3/2024
Dyne Therapeutics, Inc. announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
-
Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden
1/3/2024
Alzheon, Inc. announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for the future, at the Karolinska Institute in Stockholm, Sweden from January 18-19.
-
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
1/3/2024
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for govorestat for the treatment of Classic Galactosemia.
-
Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer
1/3/2024
Kojin Therapeutics, Inc. announced the appointment of Harvey J. Berger, M.D. as its new chairman, president, and chief executive officer.
-
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
1/3/2024
Suzhou Ribo Life Science Co., Ltd. and Ribocure AB announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
-
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
1/3/2024
Chemomab Therapeutics Ltd. announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis.
-
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
1/3/2024
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
-
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
1/3/2024
BioCardia completed 2023 with three active clinical programs of its autologous and allogeneic cell therapies to treat heart disease, with a focus on ischemic heart failure of reduced ejection fraction.
-
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
1/3/2024
UCB, a global biopharmaceutical company, announced today that ZILBRYSQ® (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
-
Microbix Achieves Further QAPs Sales RecordOver C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency
1/3/2024
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over one million Canadian Dollars of its quality assessment products to a leading agency that provides clinical laboratory accreditation services.